Several KSP inhibitors have been developed and are in various stages of clinical trials. Some notable examples include:
- Ispinesib: One of the first KSP inhibitors to enter clinical trials, it has shown promise in early-phase studies, particularly in breast cancer. - Filanesib: This inhibitor is being evaluated for its efficacy in multiple myeloma and has shown encouraging results in combination with other therapies. - SB-743921: Another KSP inhibitor under investigation, primarily in lymphomas and solid tumors.
